Danish study to track early melanoma after surgery
Part of Cancer, Skin clinical trials.
This study tests a new way to monitor people after surgery for early-stage melanoma. If you qualify, it may help your doctors watch for changes sooner or more accurately during follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and understand Danish
- You can give written informed consent
- You had surgery for melanoma stage IA to IIA within the last 3 months
- Your melanoma is not advanced (not stages IIB, IIC, III, or IV)
- You do not have a condition that greatly increases the chance of new melanoma (like dysplastic nevus syndrome or strong family history)
- You do not have medical or thinking problems that make skin self-checks impossible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different ways to manage newly diagnosed melanoma in older adults. It looks at how well surgery plus lymph node biopsy works and how it affects quality of life.
This study looks at diagnostic and prognostic factors in people who have suspicious pigmented skin lesions or melanoma that doctors are evaluating with surgery or tissue sampling. It may help improve how clinicians decide what the lesion is and what to expect over time.
This trial studies whether adding or adjusting imaging scans during follow-up after melanoma surgery can help detect recurrence earlier. It compares different follow-up imaging schedules for people at higher risk after surgery.
This trial tests a new device (Dermalyser) that estimates how thick a suspected melanoma is by analyzing a dermoscopy image. It may help doctors plan surgery without needing extra procedures.
This trial tests a personalized aftercare report for people with low-risk skin cancer. It aims to see if this report can improve follow-up care.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.